CTOs on the Move

www.mycomedica.bio

www.mycomedica.bio

 
Co-Founded by world-renowned mycologist Paul Stamets, MycoMedica, PBC is a life sciences company developing therapeutic drugs derived from fungi to help people live healthier, better lives.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

www.mycomedica.bio raised $60M on 06/01/2022

Similar Companies

AviadoBio

At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company`s technology is based on pioneering research from King`s College London and the UK Dementia Research Institute.

Imvax

The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.

Cell Signaling Technology

Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioduro-Sundia

BioDuro-Sundia provide its biopharma customers a single end-to-end solution from early stage drug discovery to late stage manufacturing.

Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.